Starting Dose for Testosterone in a 62-Year-Old Male with Hypogonadism
For a 62-year-old man with confirmed hypogonadism, start with testosterone enanthate or cypionate 200 mg intramuscularly every 2 weeks, or testosterone gel 46-50 mg daily applied to the upper arm/shoulder, with the goal of achieving mid-normal testosterone levels (450-600 ng/dL). 1
Formulation Selection
The choice between injectable and transdermal formulations should be guided by:
- Cost considerations: Injectable testosterone costs approximately $156 annually versus $2,135 for transdermal formulations 2
- Patient preference: 53% of patients prefer injectable testosterone primarily due to lower cost, while 71% of those who tried topical gel preferred it for convenience and ease of use 2
- Convenience: Transdermal gels offer daily application without injections, while injectables require less frequent administration
Injectable Testosterone Dosing
If choosing injectable testosterone enanthate or cypionate:
- Starting dose: 200 mg every 2 weeks or 100 mg weekly 1, 3
- The 200 mg every 2 weeks regimen effectively suppresses elevated LH to normal levels and maintains testosterone within the normal range 3
- Weekly dosing (100 mg) may be preferable if the patient experiences symptom cycling, early peak-related symptoms (acne, mood changes, fluid retention), or late-cycle hypogonadal symptoms (fatigue, reduced libido) 4
- More frequent dosing (twice weekly or more) should be reserved for patients who continue to experience symptom fluctuations despite weekly dosing 4
Transdermal Testosterone Dosing
If choosing transdermal gel:
- Starting dose: 46-50 mg daily applied to upper arm/shoulder 5
- This achieves an 85.5% responder rate (testosterone 300-1050 ng/dL) 5
- Dose titration is performed based on testosterone levels measured 2-8 hours after application, after at least 1 week of treatment 1
Critical Monitoring Protocol for a 62-Year-Old
At this age, prostate monitoring is mandatory 1:
Baseline (Before Starting):
- Digital rectal examination (DRE)
- PSA level
- Hematocrit
- Morning total testosterone (confirm diagnosis with repeat testing)
At 3-6 Months:
- Testosterone level: Measure midway between injections for injectables, or 2-8 hours after gel application
- Target: Mid-normal range (450-600 ng/dL)
- For injectables: If mid-interval T >600 ng/dL or <350 ng/dL, adjust dose or frequency 1
- Hematocrit: Critical safety parameter
- PSA and DRE: For men 55-69 years (your patient qualifies)
Annually Thereafter:
- Testosterone level
- Hematocrit
- PSA and DRE
- Symptom assessment
Age-Specific Safety Concerns
Hematocrit monitoring is particularly important because testosterone-induced hemoglobin increases are greater in older men 1. Stop therapy immediately if hematocrit exceeds 54%, evaluate for hypoxia and sleep apnea, and reinitiate only with a reduced dose 1.
Mandatory urological referral if 1:
- PSA increases >1.4 ng/mL within 12 months
- PSA >4.0 ng/mL at any time
- Abnormal DRE findings
- Substantial worsening of lower urinary tract symptoms
Dose Adjustment Strategy
The goal is not to maximize testosterone levels but to achieve physiologic replacement with stable symptoms 4. Before escalating the total weekly dose, consider redistributing the same dose more frequently if the patient experiences:
- Symptom cycling between injections
- Early peak-related effects (acne, mood changes, breast tenderness)
- Late-cycle hypogonadal symptoms
- Difficulty interpreting lab results due to wide peak-trough variation 4
Common Pitfalls to Avoid
- Do not use 400 mg every 4 weeks: This regimen fails to adequately suppress LH and produces suboptimal testosterone levels 3
- Do not assume every-two-week dosing is optimal for everyone: Weekly or more frequent dosing may provide better symptom stability 4
- Do not check testosterone levels at random times: Timing relative to last injection is critical for interpretation 4
- Do not continue therapy without documented symptom improvement: Reassess at 3-12 months 1